10月14日，福泰制药盘中下跌3.01%，报491.745美元/股，成交额1.42亿美元。
近期消息面上，公司此前披露其APOL1介导肾病在研药物inaxaplin在2b期试验中实现42.7%的蛋白尿降幅，合并2型糖尿病患者降幅为17.3%，且未报告药物相关严重不良事件。
公司同时表示，13周治疗后取得上述结果，且更大规模的2/3期试验已完成入组。此前多家机构亦上调或恢复覆盖该股，显示基本面预期偏积极；本次股价回落更多体现为利好兑现后的短线波动。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.